Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRAâ„¢

JERSEY CITY, N.J., April 28, 2024 /PRNewswire/ — Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement,…